

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the application of) Examiner: not assigned
J. Gregor Sutcliffe et al.)
) Group Art Unit: not assigned
For: **CORTISTATIN: NEUROPEPTIDES,**)
COMPOSITIONS AND METHODS)
Serial No.: not assigned)
Filed: January 30, 2002)
Atty. Docket No.: 22908-0002 C1)

INFORMATION DISCLOSURE
STATEMENT



Express Mail Label No.: EF 271 804 219 US

Mailed on: January 30, 2002

BOX PATENT APPLICATION

Assistant Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

Applicants wish to bring to the attention of the Patent Office the references listed on the attached form PTO-1449 and request that they be considered by the Examiner. Each of the references listed on the attached form PTO-1449 were previously cited by or submitted to the PTO in prior application Serial No. 08/857,389, filed May 15, 1997, therefore copies are not enclosed herewith.

This Information Disclosure Statement is being filed Under 37 C.F.R. §1.97(b)(3), therefore no fee is due. The Commissioner is authorized to charge any fees which may be required under 37 CFR §1.16 or §1.17, to Deposit Account No. 08-1641, referencing Atty. Docket No. 22908-0002 C1.

Respectfully submitted,

By: _____

William Schmonsees
Registration No. 31,796

Heller Ehrman White & McAuliffe LLP
275 Middlefield Road
Menlo Park, CA 94025-3506
Direct Dial: (650) 324-7041
Facsimile: (650) 324-0638
Date: January 30, 2002

#4

3503 U.S. PRO

10/062375



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR §1.56, §1.97, and §1.98 PTO-1449 FORM SHEET 1 OF 1				ATTORNEY DOCKET NO.: 22908-0002 C1	SERIAL NO.: not assigned
				APPLICANTS: J. Gregor Sutcliffe <i>et al.</i>	
				FILING DATE: January 30, 2002	GROUP ART UNIT: not assigned

U.S. PATENT DOCUMENTS						
† EX'R INITIAL	* REF. #	PATENT NUMBER	DATE (MO/YR)	NAME	U.S. CLASS/ SUBCLASS	FILING DATE (If appropriate)
	*A1	5,426,099	06/1995	Komisaruk <i>et al.</i>	514/13	

FOREIGN PATENT DOCUMENTS					
† EX'R INITIAL	* REF. #	PATENT NUMBER	DATE (MO/YR)	COUNTRY	TRANSLATION (YES/NO)
	*B1	EP 0 197 558	10/15/86	EUROPE	NO

OTHER DOCUMENTS	
† EX'R INITIAL	* REF. #
	*C1
	*C2
	*C3
	*C4
	*C5

CITATION (Author, Article Title, Journal/Book Title, Date, Pertinent Pages, etc.) De Lecea L. <i>et al.</i> : "A cortical neuropeptide with neuronal depressant and sleep-modulating properties" NATURE, 381:242-245 (5/16/96). Fukusumi S. <i>et al.</i> : "Identification and characterization of a novel human Cortistatin-like peptide" BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 232(1):157-163 (3/6/97). Tostivint H. <i>et al.</i> : "Un deuxième gène codant pour la somatostatine est exprimé dans le cerveau" M/S (MEDECINE/SCIENCES) MINI-SYNTHESE, 12(10):1131-1133 (10/96). Prospero-Garcia O <i>et al.</i> : "Cortistatin modulates cortical and hippocampal electrophysiological activity and sleep" SOCIETY FOR NEUROSCIENCE ABSTRACTS: 26TH ANNUAL MEETING, WASHINGTON, D.C., USA., 22(1-3):1152 (11/16/96 - 11/21/96). De Lecea L. <i>et al.</i> : "Cloning, mRNA expression, and chromosomal mapping of mouse and human Preprocortistatin" GENOMICS, 42(3):499-506 (6/15/97).	
--	--

EXAMINER'S SIGNATURE	DATE CONSIDERED
----------------------	-----------------

† EXAMINER: Initial if reference is considered, whether or not citation is in conformance with MPEP 609. Line through citation if not in conformance and not considered. Include copy of this form in next communication to applicant.

* If an asterisk is placed beside the reference number, a copy is not provided because the reference was previously cited by or submitted to the PTO in a prior application that is identified in the statement and relied upon for an earlier filing date under 35 U.S.C. 120. 37 C.F.R. 1.98(d).